Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Victoza vs Lyxumia in T2DM Gastroesophageal Reflux
NCT02231658Phase 1Terminated
- Sponsor
- Profil
- Start
- Jul 2015
- Primary completion
- Jul 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in type 2 diabetes mellitus (T2DM) comparing Victoza Arm with Lyxumia Arm (2 arms). Primary endpoint: Change from baseline in the number of reflux episodes at 10 weeks. Started Jul 2015; status: terminated.
02
Drugs
liraglutidelixisenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02231658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02231658.